PTC Therapeutics, Inc.
PTCT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3 | $2 | $3 | $3 |
| - Cash | $1 | $1 | $0 | $0 |
| + Debt | $2 | $2 | $1 | $1 |
| Enterprise Value | $5 | $4 | $4 | $4 |
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | -14% | 34.2% | 29.7% | – |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 92.9% | 93% | 93.6% | 94% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -14.9% | -35.2% | -52.6% | -68.4% |
| Net Income | -$0 | -$1 | -$1 | -$1 |
| % Margin | -45% | -66.8% | -80% | -97.3% |
| EPS Diluted | -4.73 | -8.37 | -7.79 | -7.43 |
| % Growth | 43.5% | -7.4% | -4.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$1 | -$0 |